On 9 February 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published new guidance for UK Marketing Authorisation Holders outlining how pharmacovigilance requirements will apply following amendments to Commission Implementing Regulation (CIR) 520/2012. The guidance reflects the European Commission’s adoption of Regulation (EU) 2025/1466, which revises CIR 520/2012 and becomes applicable from 12 February 2026, with limited provisions effective from 12 August 2025. The update is particularly relevant for organisations holding UK-authorised medicinal products across different categories under the Windsor Framework.
Details of the Update
The guidance explains that CIR 520/2012 has been formally amended by Regulation (EU) 2025/1466, introducing changes to pharmacovigilance requirements. Following implementation of the Windsor Framework, UK-authorised medicinal products are now classified as Category 1 or Category 2, which determines the applicable legal framework.
From 12 February 2026, HMR 2012 Schedule 12A and the amended CIR 520/2012 will no longer be legally aligned for pharmacovigilance obligations. This divergence means that different requirements may apply depending on product category and portfolio structure.
To reduce unnecessary regulatory burden, MHRA outlines a pragmatic compliance approach. Marketing Authorisation Holders with mixed portfolios containing both Category 1 and Category 2 products are advised to apply the amended CIR 520/2012 across all UK-authorised products. In contrast, holders with Category 1 products only may continue to follow HMR Schedule 12A, unless they also hold equivalent European Union authorisations, in which case additional considerations apply.
MHRA also notes that future updates to HMR 2012 Schedule 12A may be considered to better reflect the amendments made to CIR 520/2012, although no changes have been confirmed at this stage.
Effective Date
The amended Commission Implementing Regulation (CIR) 520/2012, as revised by Regulation (EU) 2025/1466, applies from 12 February 2026. However, Articles 1(7) and 1(9) of the amending regulation took effect earlier, on 12 August 2025.
Why It Matters
This update introduces non-alignment between UK and EU pharmacovigilance legal frameworks, creating practical implications for compliance planning. While MHRA’s pragmatic approach aims to support regulatory clarity, operational efficiency, and digital alignment, it also requires organisations to carefully manage processes to avoid misapplication of requirements. The changes may necessitate targeted updates to pharmacovigilance systems, governance structures, and internal procedures, particularly for organisations with complex or mixed product portfolios.
Who This Is Relevant For
The guidance is relevant for Pharmacovigilance, Regulatory Affairs, Quality Assurance, Compliance, and IT or digital governance teams involved in managing UK-authorised medicinal products and cross-jurisdictional regulatory obligations.
Next Steps
Organisations should review their UK product portfolios to confirm whether products fall under Category 1 or Category 2 and assess the presence of any EU-equivalent licences. Internal pharmacovigilance procedures, decision frameworks, and governance models should be checked against the clarified expectations, with cross-functional alignment ahead of the 12 February 2026 effective date to minimise compliance risk.
As regulatory divergence increases operational complexity, having a structured way to monitor changes and assess their impact becomes increasingly important. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organisations in highly regulated sectors, including life sciences, to proactively navigate evolving regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely, predictive, and actionable insights, helping teams streamline compliance processes and maintain oversight across more than 160 countries. Learn more or book a demo now.
FAQs
What is Commission Implementing Regulation 520/2012?
It is an EU regulation that sets out detailed pharmacovigilance requirements for medicinal products, including obligations for Marketing Authorisation Holders.
What changed under Regulation (EU) 2025/1466?
Regulation (EU) 2025/1466 amends CIR 520/2012, revising pharmacovigilance requirements and applying from 12 February 2026, with limited provisions effective from 12 August 2025.
How does the Windsor Framework affect UK pharmacovigilance obligations?
The Windsor Framework introduces Category 1 and Category 2 classifications for UK-authorised medicinal products, resulting in different applicable legal frameworks for pharmacovigilance.
How can RegASK help organisations manage these changes?
RegASK helps teams track regulatory updates, assess portfolio-specific impact, and coordinate compliance workflows, enabling more efficient management of diverging UK and EU pharmacovigilance requirements.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
